Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 5

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
US GENE LAB CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 

AS OF JUNE 30, 2025 AND 2024 

(Amount expressed in United States Dollars (“US$)) 

(Unaudited)

  Common stock  Additional      Accumulated other  Total   Number of shares  Amount   paid in capital  Accumulated deficit  comprehensive losses  stockholders’equity Balance as of December 31, 2023 *1,766,766  $17,191,315  $(5,011,891) $(1,844,278) $(677,294) $9,657,852 Net loss for the period  -   -   -   (103,757)  -   (103,757)Foreign currency translation loss  -   -   -   -   (209,908)  (209,908)Balance as of March 31, 2024 *1,766,766  $17,191,315  $(5,011,891) $(1,948,035) $(887,202) $9,344,187 Net profit for the period  -   -   -   199,104   -   199,104 Foreign currency translation gain  -   -   -   -   2,463   2,463 Balance as of June 30, 2024 *1,766,766  $17,191,315  $(5,011,891) $(1,748,931) $(884,739) $9,545,754 

  Common stock  Additional     Accumulated other  Total   Number of shares  Amount   paid in capital  Accumulated deficit  comprehensive losses  stockholders’equity Balance as of December 31, 2024 *1,796,766  $17,332,315  $(5,011,891) $(3,442,620) $(555,000) $8,322,804 Net loss for the period